Top Markets
#1 龙虾 (Lobster) 龙虾 (Lobster) +86.21%
#2 Cortex Cortex +56.70%
#3 Lisk Lisk +55.59%
#4 AI XOVIA AI XOVIA +41.25%
#5 Merlin's Seal BTC Merlin's Seal BTC +29.19%
#6 earnAUSD earnAUSD +24.75%
#7 Nockchain Nockchain +23.91%
#8 UnifAI Network UnifAI Network +20.32%
#9 VeThor VeThor +18.00%
#10 Collector Crypt Collector Crypt +17.17%
Coin of the day
龙虾 (Lobster) 龙虾 (Lobster)
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Classifica tra le azioni #171
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily... Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
Prezzo delle azioni
$515.86
Ultima sincronizzazione: 2026-09-11
Capitalizzazione di mercato
$130.93B
Variazione (1 giorno)
0.25%
Variazione (1 anno)
30.75%
Paese
US
Scambia Vertex Pharmaceuticals Incorporated (VRTX)

Categoria

Healthcare
Storico del prezzo dell'azione per Vertex Pharmaceuticals Incorporated (VRTX)
Prezzo di chiusura più alto: $536.00 il 2026-09-01

Prezzo di chiusura più basso: $197.34 il 2021-08-01
Storico del prezzo dell'azione di Vertex Pharmaceuticals Incorporated dal 2021 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) 1.34%
2025 1.92%
2024 15.46%
2023 25.61%
2022 43.24%
2021 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $987.47 30.55%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $146.64 523.73%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $117.15 -15.24%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $690.34 0.44%
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $246.25 1.17%
BE